Bristol-Myers Squibb Co vs Valero Energy Corporation — how do they compare? Bristol-Myers Squibb Co trades at $63.74 (market cap $129.94B), while Valero Energy Corporation trades at $325.8 (market cap $93.27B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (3.96%). Which is the better fit depends on your goals.
| BMY | VLO | |
|---|---|---|
Market Cap | $129.94B | $93.27B |
Sector | Health | Energy |
52-Week High | $65.89 | $323.92 |
52-Week Low | $42.60 | $133.38 |
Enterprise Value | $163.92B | $96.74B |
Dividend Yield | 3.96% | 1.48% |
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $64.84, up 0.19% today, with a bullish technical signal from moving averages and strong fundamental health evidenced by a 14.01 P/E ratio and 18.87% net income margin. Recent earnings beats and a $2.3 billion manufacturing investment in Houston highlight operational strength, while analyst consensus is mixed with a $68.56 price target.
The outlook is positive due to earnings momentum and strategic investments, but risks include patent expirations and high debt levels. Wall Street sentiment is cautiously optimistic, with institutional buying supporting the stock's potential for moderate upside from current levels.
Valero Energy (VLO) trades at $314.95, up 5.58% in 24 hours, reflecting strong momentum. The stock exhibits bullish technical signals with key support at $307 and resistance at $324. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $12.54 surpassing the $10.11 estimate. Revenue for 2026 is projected to rise to $139.4 billion, with net income margin improving to 5.17%.
Outlook remains positive due to robust refining margins and renewable diesel growth, but risks include volatile oil prices and geopolitical tensions. Analysts maintain a buy consensus with a $324.27 price target, indicating potential upside. Investors should monitor execution on earnings guidance and global energy supply dynamics.
Trailing returns across standard periods
Latest headlines on both assets
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →